KALA BIO
Waltham
About KALA BIO
Kala Bio is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus-penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet needs. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $580.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Feb 2026)
- Ticker: nasdaq:KALA
- Website: kalarx.com
- Phone: 1(781) 996-5252
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/kala-bio-89462 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.